Division of Allergy-Immunology, Children's Hospital of Philadelphia, Philadelphia, Pa.
Division of Allergy-Immunology, Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
J Allergy Clin Immunol. 2018 Dec;142(6):1740-1747. doi: 10.1016/j.jaci.2018.10.012. Epub 2018 Oct 22.
This review encompasses relevant scientific and clinical advances in atopic dermatitis (AD) published in 2017. These include articles from the Journal of Allergy and Clinical Immunology, as well as other prominent publications that have contributed to the emerging field, on the microenvironment of the skin and molecular patterns guiding biologic treatment strategies. The most commonly questioned and explored themes of the year included the effect of the microbiome on AD development, as well as cell signaling and symptom severity. Topics also included the description of patient-specific molecular endotypes within the larger population with AD. All of these factors will create potential opportunities to guide personalized therapy with the broadening array of topical and systemic interventions currently available, as well as providing new insights to guide the development of novel molecularly targeted therapeutics. With recent US Food and Drug Administration approval of the first wave of new targeted therapies for AD, additional information exploring the safety profiles and long-term effects of these medications was also at the forefront in 2017.
这篇综述涵盖了 2017 年发表的特应性皮炎（AD）相关的科学和临床进展。其中包括《过敏与临床免疫学杂志》（Journal of Allergy and Clinical Immunology）的文章，以及其他为这一新兴领域做出贡献的知名出版物，内容涉及皮肤微环境和指导生物治疗策略的分子模式。当年最常被质疑和探讨的主题包括微生物组对 AD 发展的影响，以及细胞信号转导和症状严重程度。还有一些主题涉及描述 AD 大患者群体中的特定分子内表型。所有这些因素都将为指导个性化治疗提供潜在机会，当前有大量的局部和全身干预措施可供选择，同时也为指导新型分子靶向治疗的发展提供新的见解。最近美国食品和药物管理局（FDA）批准了第一批用于 AD 的新型靶向治疗药物，因此 2017 年也处于探索这些药物的安全性和长期疗效的前沿。
